These findings further underscore the potential role of VEGF in driving pathological processes in vascular smooth muscle and endothelial cells in CTD-PAH patients, culminating in pulmonary vascular remodeling and heightened PVR. This evidence concerns the gene VEGFA and pulmonary arterial hypertension.